IPBA

Inflection Point Biomedical Advisors

Inflection Point Biomedical Advisors provides effective strategic advice and implement hands-on, innovative projects in Precision Medicine for the pharmaceutical and diagnostics industry, investment and VC funds as well as to the EU and US governmental agencies.

IPBA is a key collaborator and vital partner of Article25 Capital.

news

News Highlights – March 2021
07/04/2021

News Highlights – March 2021


March 2021 witnessed interesting developments in the landscape of precision oncology. Several companies joined forces to expand their portfolio of NGS solutions and optimize data management, including Bio-techne, Agilent and Merck, making a tender offer for the public stocks of Pandion Therapeutics.

Among this month's FDA drug approvals, Pfizer’s Lorbrena (Lornatinib) indication was extended as a first-line treatment for ALK-positive NSCLC patients, along with Ventana ALK IHC test as its CDx. In addition, Spectrum Pharmaceuticals’ poziotinib, received a fast track designation for HER2-exon-20-mutant NSCLC patients, addressing a large unmet need. Further immunotherapies received marketing approvals for breast cancer, urothelial carcinoma and renal cell cancer.

Liquid biopsy has seen a fast change in the landscape, with Guardant and FMI expanding access in different geographies and starting to redefine the testing practice.

View
Centralisation in the time of pandemic
26/04/2020

Centralisation in the time of pandemic

This third article in our series, deciphering the diagnostic testing organisation in the UK, recapitulates lessons learned from local initiatives during the COVID-19 pandemic to adjust the current centralisation of tests.

View